It’s thought AstraZeneca and Johnson & Johnson vaccines could be used again, with some modifications.
German researchers claim they know how to avoid blood clots that have appeared in connection with the AstraZeneca and Janssen vaccines.
It is the big newspaper Financial times Who reports this late on a Wednesday night.
The problem with vaccines is the adenovirus vectors that both vaccines use, according to Rolf Marshallek, a professor at Goethe University in Frankfurt, who led a team Research work On the rare side effects since March.
The two vaccines send the prickly protein to the cell’s nucleus, instead of the cell’s cell fluid. Once inside the nucleus, certain parts of the spike protein are bound together. This is the beginning of the causes of rare blood clots, says Marshlik.
On the other hand, the BioNTech / Pfizer and Moderna vaccines do not enter the cell nucleus, he says. He believes that there is an easy way to prevent the spike protein from splicing, that is, by changing its sequence.
“With the data we have in our hands, we can tell companies how to alter these sequences, and encode the spike protein in a way that prevents unintended interactions,” Marshallk told the Financial Times.
Johnson & Johnson has already contacted the German university to request guidance, according to Marshallik, who adds that the latter’s vaccine actually has a lower chance of splitting than the AstraZeneca vaccine.
Some researchers, advocating among other things a causal chain, have written warning that Marshallik’s theory is one of many, and that more evidence is needed to substantiate his claims, the Financial Times writes.
Pørni breaks all records – here you see the series for free